Increased brain uptake of gamma-aminobutyric acid in a rabbit model of hepatic encephalopathy.
Transfer of the inhibitory neurotransmitter gamma-aminobutyric acid across the normal blood-brain barrier is minimal. One prerequisite for gamma-aminobutyric acid in plasma contributing to the neural inhibition of hepatic encephalopathy would be that increased transfer of gamma-aminobutyric acid across the blood-brain barrier occurs in liver failure. The aim of the present study was to determine if brain gamma-aminobutyric acid uptake is increased in rabbits with stage II-III (precoma) hepatic encephalopathy due to galactosamine-induced fulminant hepatic failure. A modification of the Oldendorf intracarotid artery-injection technique was applied. [3H] gamma-aminobutyric acid, [14C] butanol, and 113mIn-labeled serum protein (transferrin) were injected simultaneously 4 s before decapitation. The ipsilateral brain uptake index of gamma-aminobutyric acid was determined from measurements of the 3 isotopes in 5 brain regions. Uncorrected or simple brain uptake indices of [3H] gamma-aminobutyric acid and [113mIn] transferrin were calculated using [14C] butanol as the highly extracted reference compound. The [113mIn] transferrin data were also used to "correct" the brain uptake index of [3H] gamma-aminobutyric acid for intravascular retention of [3H] gamma-aminobutyric acid. The methodology adopted minimized problems attributable to rapid [3H] gamma-aminobutyric acid metabolism, and slow brain washout and recirculation of the radiolabeled tracers. Both the uncorrected and corrected brain uptake indices of gamma-aminobutyric acid as well as the simple brain uptake index of transferrin were significantly increased in both stage II and III hepatic encephalopathy in all brain regions studied. Moreover, these brain uptake indices were significantly greater in stage III hepatic encephalopathy than in stage II hepatic encephalopathy. These findings indicate that transfer of gamma-aminobutyric acid from plasma to brain extracellular fluid is increased in the model of hepatic encephalopathy studied; hence, they provide support for the hypothesis that plasma-derived gamma-aminobutyric acid may contribute to the neural inhibition of hepatic encephalopathy due to fulminant hepatic failure.
Bassett
M L
ML
Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Mullen
K D
KD
Scholz
B
B
Fenstermacher
J D
JD
Jones
E A
EA
D000818:Animals; D001921:Brain / Q000378:metabolism*; D000440:Butanols / Q000008:administration & dosage; D002250:Carbon Radioisotopes; D004195:Disease Models, Animal; D005688:Galactosamine / Q000633:toxicity; D006207:Half-Life; D006501:Hepatic Encephalopathy / Q000139:chemically induced / Q000378:metabolism*; D007205:Indium Radioisotopes; D008722:Methods; D011817:Rabbits; D013997:Time Factors; D014168:Transferrin / Q000008:administration & dosage; D014316:Tritium; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000493:pharmacokinetics*
D000440:Butanols; D002250:Carbon Radioisotopes; D007205:Indium Radioisotopes; D014168:Transferrin; D014316:Tritium; D005680:gamma-Aminobutyric Acid; D005688:Galactosamine